Necrotizing fungal osteomyelitis and fingolimodNecrotizing fungal osteomyelitis, 4 years after treatment with fingolimod

Publication date: Available online 22 February 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Mohammad Hossein Harirchian, Maryam Poursadeghfard, Alireza Sadeghipour, Hoda Kamali, Payam SarrafAbstractFingolimod has been the first approved oral medication in MS for its relapsing remitting type. It is a non-selective sphingosine1-phosphate (S1P) receptor modulator on lymphocytes. Engagement of this receptor blocks the T cells and B cells migration from the lymph nodes into the inflamed central nervous system (CNS) via bloodstream. In spite of this known immunomodulatory mechanism, there are some reports about serious infection following the initiation of fingolimod therapy like herpes types or infections associated to the immunosuppressed situation (cryptococcal meningitis, primary cutaneous cryptococcosis and visceral leishmaniasis). To the best of our knowledge, in contrary to many reports about opportunistic or serious infections with fingolimod, there has been no report on fungal osteomyelitis associated to fingolimod until now. Here, we aimed to describe a woman who developed necrotizing fungal osteomyelitis four years after starting fingolimod, as a disease modifying drug for MS.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 29 May 2020Source: Carbohydrate PolymersAuthor(s): Noha Hesham Radwan, Maha Nasr, Rania A.H. Ishak, Nourtan F. Abdeltawab, Gehanne A.S. Awad
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
Publication date: Available online 29 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Helena Beatriz Ferreira, Bruna Neves, Inês M. Guerra, Ana Moreira, Tânia Melo, Artur Paiva, M. Rosário Domingues
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
CONCLUSION: On the basis of a broadly based research and participatory development process, a set of indicators has been developed that enables comprehensive evaluation of the regional quality of care of cross-indication, integrated care models focusing on common diseases. In order to be able to increasingly evaluate aspects of care coordination and patient orientation, health promotion as well as nursing, palliative and emergency care in the future, it would be helpful if routine data were collected or made accessible in these areas as well. PMID: 32467041 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen - Category: Health Management Tags: Z Evid Fortbild Qual Gesundhwes Source Type: research
TRIUMPHANT, a new placebo-controlled trial, has not shown any benefit over placebo of three different drugs commonly used to treat fatigue in patients with multiple sclerosis.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Conditions:   Multiple Sclerosis;   Menstrual Pain;   Anxiety;   Fatigue;   Neurologic Symptoms Interventions:   Other: pain;   Other: fatigue;   Other: anxiety;   Other: position sense;   Other: balance;   Other: dual task performance Sponsor:   Ankara Yildirim Beyazıt University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Multiple Sclerosis;   Traumatic Brain Injury Interventions:   Behavioral: Emotional Processing Training;   Behavioral: Placebo Control Sponsor:   Kessler Foundation Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Multiple Sclerosis;   Menstrual Pain;   Anxiety;   Fatigue;   Neurologic Symptoms Interventions:   Other: pain;   Other: fatigue;   Other: anxiety;   Other: position sense;   Other: balance;   Other: dual task performance Sponsor:   Ankara Yildirim Beyazıt University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 28 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Konstantin Balashov, Suhayl Dhib-Jalbut, Igor Rybinnik
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Cryptococcosis | Gilenya | Herpes | Men | Meningitis | Multiple Sclerosis | Neurology | Osteomyelitis